406 related articles for article (PubMed ID: 27176041)
1. Novel treatments for rare rheumatologic disorders: analysis of the impact of 30 years of the US orphan drug act.
Lutz T; Lampert A; Hoffmann GF; Ries M
Orphanet J Rare Dis; 2016 May; 11(1):60. PubMed ID: 27176041
[TBL] [Abstract][Full Text] [Related]
2. Novel Treatments for Rare Cancers: The U.S. Orphan Drug Act Is Delivering-A Cross-Sectional Analysis.
Stockklausner C; Lampert A; Hoffmann GF; Ries M
Oncologist; 2016 Apr; 21(4):487-93. PubMed ID: 27022038
[TBL] [Abstract][Full Text] [Related]
3. Pressure for drug development in lysosomal storage disorders - a quantitative analysis thirty years beyond the US orphan drug act.
Mechler K; Mountford WK; Hoffmann GF; Ries M
Orphanet J Rare Dis; 2015 Apr; 10():46. PubMed ID: 25896727
[TBL] [Abstract][Full Text] [Related]
4. Ethical imperatives of timely access to orphan drugs: is possible to reconcile economic incentives and patients' health needs?
Rodriguez-Monguio R; Spargo T; Seoane-Vazquez E
Orphanet J Rare Dis; 2017 Jan; 12(1):1. PubMed ID: 28057032
[TBL] [Abstract][Full Text] [Related]
5. What the Orphan Drug Act has done lately for children with rare diseases: a 10-year analysis.
Thorat C; Xu K; Freeman SN; Bonnel RA; Joseph F; Phillips MI; Imoisili MA
Pediatrics; 2012 Mar; 129(3):516-21. PubMed ID: 22371464
[TBL] [Abstract][Full Text] [Related]
6. Investigating the landscape of US orphan product approvals.
Miller KL; Lanthier M
Orphanet J Rare Dis; 2018 Oct; 13(1):183. PubMed ID: 30348193
[TBL] [Abstract][Full Text] [Related]
7. Using four decades of FDA orphan drug designations to describe trends in rare disease drug development: substantial growth seen in development of drugs for rare oncologic, neurologic, and pediatric-onset diseases.
Miller KL; Fermaglich LJ; Maynard J
Orphanet J Rare Dis; 2021 Jun; 16(1):265. PubMed ID: 34107994
[TBL] [Abstract][Full Text] [Related]
8. Precision Medicines' Impact on Orphan Drug Designation.
Mueller CM; Rao GR; Miller Needleman KI
Clin Transl Sci; 2019 Nov; 12(6):633-640. PubMed ID: 31297924
[TBL] [Abstract][Full Text] [Related]
9. A comprehensive study of the rare diseases and conditions targeted by orphan drug designations and approvals over the forty years of the Orphan Drug Act.
Fermaglich LJ; Miller KL
Orphanet J Rare Dis; 2023 Jun; 18(1):163. PubMed ID: 37353796
[TBL] [Abstract][Full Text] [Related]
10. Thirty Years of Orphan Drug Legislation and the Development of Drugs to Treat Rare Seizure Conditions: A Cross Sectional Analysis.
Döring JH; Lampert A; Hoffmann GF; Ries M
PLoS One; 2016; 11(8):e0161660. PubMed ID: 27557111
[TBL] [Abstract][Full Text] [Related]
11. Incentives for orphan drug research and development in the United States.
Seoane-Vazquez E; Rodriguez-Monguio R; Szeinbach SL; Visaria J
Orphanet J Rare Dis; 2008 Dec; 3():33. PubMed ID: 19087348
[TBL] [Abstract][Full Text] [Related]
12. Database identifies FDA-approved drugs with potential to be repurposed for treatment of orphan diseases.
Xu K; Coté TR
Brief Bioinform; 2011 Jul; 12(4):341-5. PubMed ID: 21357612
[TBL] [Abstract][Full Text] [Related]
13. Pediatric Orphan Drug Indications: 2010-2018.
Kimmel L; Conti RM; Volerman A; Chua KP
Pediatrics; 2020 Apr; 145(4):. PubMed ID: 32127360
[TBL] [Abstract][Full Text] [Related]
14. Patient-Reported Outcomes in Orphan Drug Labels Approved by the US Food and Drug Administration.
Hong YD; Villalonga-Olives E; Perfetto EM
Value Health; 2019 Aug; 22(8):925-930. PubMed ID: 31426934
[TBL] [Abstract][Full Text] [Related]
15. Orphan medicinal products in Europe and United States to cover needs of patients with rare diseases: an increased common effort is to be foreseen.
Giannuzzi V; Conte R; Landi A; Ottomano SA; Bonifazi D; Baiardi P; Bonifazi F; Ceci A
Orphanet J Rare Dis; 2017 Apr; 12(1):64. PubMed ID: 28372595
[TBL] [Abstract][Full Text] [Related]
16. The impact of the Orphan Drug Act on Food and Drug Administration-approved therapies for rare skin diseases and skin-related cancers.
Karas L; Lu CY; Agrawal PB; Asgari MM
J Am Acad Dermatol; 2019 Sep; 81(3):867-877. PubMed ID: 31103566
[TBL] [Abstract][Full Text] [Related]
17. The US Orphan Drug Act: rare disease research stimulator or commercial opportunity?
Wellman-Labadie O; Zhou Y
Health Policy; 2010 May; 95(2-3):216-28. PubMed ID: 20036435
[TBL] [Abstract][Full Text] [Related]
18. FDA orphan drug designations for lysosomal storage disorders - a cross-sectional analysis.
Garbade SF; Zielonka M; Mechler K; Kölker S; Hoffmann GF; Staufner C; Mengel E; Ries M
PLoS One; 2020; 15(4):e0230898. PubMed ID: 32267884
[TBL] [Abstract][Full Text] [Related]
19. Effective Market Exclusivity of New Molecular Entities for Rare and Non-rare Diseases.
Kerr KW; Glos LJ
Pharmaceut Med; 2020 Feb; 34(1):19-29. PubMed ID: 32048213
[TBL] [Abstract][Full Text] [Related]
20. Evaluating The Impact Of The Orphan Drug Act's Seven-Year Market Exclusivity Period.
Sarpatwari A; Beall RF; Abdurrob A; He M; Kesselheim AS
Health Aff (Millwood); 2018 May; 37(5):732-737. PubMed ID: 29733729
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]